Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3303742 | 0.99 | PTGS1 (0.45) | PTGS1PTGS2LMNACA12CA1 | |
| SCHEMBL3305810 | 0.97 | LMNA (0.44) | PTGS1PTGS2LMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL3305333 | 0.96 | LMNA (0.43) | PTGS1PTGS2LMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL4430268 | 0.96 | LMNA (0.43) | PTGS1PTGS2LMNACA12CA1 | |
| SCHEMBL28432701 | 0.88 | PTGS1 (0.42) | PTGS1PTGS2LMNACA12CA1 | |
| SCHEMBL3310195 | 0.87 | PTGS2 (0.49) | PTGS1PTGS2LMNACA12CA1 | |
| SCHEMBL3310196 | 0.87 | PTGS2 (0.49) | PTGS1PTGS2LMNACA12CA1 | |
| SCHEMBL3309307 | 0.85 | PTGS1 (0.41) | PTGS1PTGS2LMNAGRIK1ANPEP | |
| SCHEMBL28758664 | 0.84 | PTGS1 (0.47) | PTGS1PTGS2LMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL3306995 | 0.84 | PTGS1 (0.40) | PTGS1PTGS2LMNAGRIK1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | claimed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | claimed |
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2131830-A2 | PHARMACEUTICAL FORM WITH IMPEDED ABUSE | Grünenthal GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107149-A2 | PHARMACEUTICAL FORM WITH IMPEDED ABUSE | Grünenthal GmbH (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PTGS1 8/4885PTGS2 15/4885LMNA 4506/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PTGS1 7/4885PTGS2 12/4885LMNA 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.